Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases
- 6 August 2020
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (9) , 3259-3267
Abstract
Circulating tumor DNA (ctDNA) is a promising technology for treatment selection, prognostication, and surveillance after definitive therapy. Its use in theKeywords
Funding Information
- Joan and Irwin Jacobs Fund philanthropic fund
- National Cancer Institute (CA023100)
- National Institutes of Health (TL1TR001443)
- Guardant Health
This publication has 27 references indexed in Scilit:
- Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced MalignanciesJCO Precision Oncology, 2019
- Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and SurvivalJCO Precision Oncology, 2019
- Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan‐cancer settingInternational Journal of Cancer, 2019
- Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast MalignanciesMolecular Cancer Therapeutics, 2019
- Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaClinical Cancer Research, 2018
- Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free SurvivalAnnals of Surgical Oncology, 2018
- MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosisJournal of Hematology & Oncology, 2018
- The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNAMolecular Cancer Therapeutics, 2017
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionCancer Discovery, 2017
- Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancerMolecular Oncology, 2015